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Ischemic injury represents the most frequent cause of death and
disability, and it remains unclear why, of all body organs, the brain
is most sensitive to hypoxia. In many tissues, type 4 NADPH
oxidase is induced upon ischemia or hypoxia, converting oxygen
to reactive oxygen species. Here, we show in mouse models of
ischemia in the heart, brain, and hindlimb that only in the brain
does NADPH oxidase 4 (NOX4) lead to ischemic damage. We ex-
plain this distinct cellular distribution pattern through cell-specific
knockouts. Endothelial NOX4 breaks down the BBB, while neuro-
nal NOX4 leads to neuronal autotoxicity. Vascular smooth muscle
NOX4, the common denominator of ischemia within all ischemic
organs, played no apparent role. The direct neuroprotective po-
tential of pharmacological NOX4 inhibition was confirmed in an ex
vivo model, free of vascular and BBB components. Our results dem-
onstrate that the heightened sensitivity of the brain to ischemic
damage is due to an organ-specific role of NOX4 in blood–brain-
barrier endothelial cells and neurons. This mechanism is conserved
in at least two rodents and humans, making NOX4 a prime target
for a first-in-class mechanism-based, cytoprotective therapy in
the unmet high medical need indication of ischemic stroke.
NOX4 | stroke | BBB | neurotoxicity | endothelium
Ischemic and/or hypoxic disease states such as myocardial in-farction (MI), peripheral artery disease, and stroke collectively
represent the most frequent causes of death and disability (1).
However, their underlying mechanisms and cellular interplay
leading to organ damage and chronic loss of function are in-
completely understood. Consequently, treatments of these con-
ditions are currently restricted to the symptomatic removal of the
occlusion (2) without also using therapies directed to preserve
organ function (3).
One pathomechanism that has been put forward as a possible
cause of postischemic cell death and organ dysfunction is oxi-
dative stress (4, 5), i.e., the appearance of reactive oxygen species
(ROS) in either unphysiological locations or at unphysiological
levels. However, global ROS-scavenging antioxidants provide
little or no protection in this scenario (6, 7), arguing against the
oxidative stress hypothesis (8). A recent alternative approach to
oxidative stress focuses on the disease-relevant enzymatic sour-
ces of ROS and their pharmacological inhibition (4, 5).
NADPH oxidases (NOX) are one of the main sources of ROS
and, importantly, the only known enzyme family that has ROS
formation as its sole known function (4). Of these, NOX4 appears
most relevant as a target for therapy, as it is induced under ischemia
or hypoxia in different cells and tissues (9–11) and may be a long-
sought common denominator of ischemia-reperfusion (IR) injury
(12). We here test this hypothesis in three mouse models of the
most relevant ischemic disease states, all associated also with in-
creased ROS formation: MI (13), peripheral artery disease (13),
and stroke (14). We also validate the role of NOX4 in a relevant rat
in vivo and in human in vitro models.
Results
Postischemic Injury Depends on NOX4 in Stroke but Not in MI or
Hindlimb Ischemia. To elucidate whether hypoxia-inducible NOX4-
derived ROS is a systemic mechanism of ischemic tissue dam-
age, we investigated three different in vivo mouse models re-
lated to three highly relevant ischemic disease conditions: MI
and transient ischemia of the heart, peripheral artery disease,
and stroke. First, relative Nox4 gene expression was evaluated
in heart and hindlimb muscle in wild-type (WT) mice (8–16 wk)
subjected to MI and hindlimb ischemia, respectively, and com-
pared with nonischemic mice. Nox4 was up-regulated after ische-
mia in all these models, including both in vivo and in vitro models
of brain ischemia (SI Appendix, Fig. S1).
For stroke, 8- to 12-wk-old male global Nox4 KO mice were
subjected to 1 h of transient middle cerebral artery occlusion
(tMCAO) and 24 h of reperfusion. Consistent with our previous
findings, Nox4 KO mice developed significantly smaller brain
infarct sizes compared with the WT group (Fig. 1A). Likewise,
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permanent occlusion of the middle cerebral artery in Nox4 KO
mice showed the same infarct size reduction as in the transient
occlusion (9).
To investigate the role of NOX4 in hindlimb ischemia, which
mimics human peripheral artery disease, sexually mature adult
Nox4 KO and WT mice from 12 to 16 wk old were subjected to
permanent ligation of the femoral artery. Angiogenesis (sprouting
of new capillaries) occurs as a response to the ischemic muscle
damage, mainly in the distal calf muscles (13), and was assessed via
the capillary density marker, CD31, at day 28 as reported pre-
viously (11) and well within the reported range of 14 and 35 d
postligation (15). No significant differences were observed in the
gastrocnemius (Fig. 1B) or adductor muscle (Fig. 1C) in Nox4 KO
mice versus WT littermates. Similarly, blood flow restoration was
not modified by global Nox4 deficiency (Fig. 1D).
We also investigated the possible role of NOX4 in MI and
IR of the heart after permanent and transient (45 min) occlusion of
the left descending coronary artery in 8- to 12-wk-old Nox4 KO
mice. Infarct sizes, assessed by AZAN stain 4 wk after MI or IR,
were similar in Nox4 KO and WT mice (Fig. 1E and SI Appendix,
Fig. S2A). Functionally, ejection fraction at 2 and 4 wk post-MI or
post-IR were not different between Nox4 KO andWT mice (Fig. 1F
and SI Appendix, Fig. S2B). Furthermore, a change in maximal and
minimal first derivative of left ventricle (LV) pressure (LV dP/
dtmax, min) in response to increasing doses of dobutamine is an
excellent and sensitive measure of in vivo β-adrenergic receptor
function. However, the contractility and relaxing capacity of post-MI
hearts were not altered in Nox4 KO mice after MI (Fig. 1G) or IR
(SI Appendix, Fig. S2C). To improve the temporal comparability of
the heart data to the tMCAO model, short-term experiments with
45 min of ischemia and 24 h of reperfusion also were performed.
Infarct sizes, as assessed by tetrazolium chloride (TTC) stain, did not
differ between WT and NOX4 KO mice (SI Appendix, Fig. S2D).
Also, the functional parameters, ejection fraction (SI Appendix, Fig.
S2E), and contractility (SI Appendix, Fig. S2F) were similar in WT
and Nox4 KO mice. Thus, although NOX4 was up-regulated in all
three ischemic models, deletion of Nox4 did not modify outcomes
after ischemia of the heart nor of the hindlimb. Deletion of Nox4,
however, conveyed a major a protective in stroke, indicating a sur-
prising highly organ-specific role of NOX4.
As a possible explanations for this, the blood–brain barrier
(BBB) is a unique feature of the brain versus heart and skeletal
muscle and, in ischemic cerebrovascular smooth muscle cells
(SMCs), NOX4 impairs myogenic tone (15). We therefore in-
vestigated the contribution of both vascular cell types, endo-
thelial and vascular smooth muscle. Moreover, as some neurons
were also NOX4 immunopositive (9), we also investigated
neuron-specific Nox4 KO mice (Fig. 2A).
Cell-Specific Nox4 KO Mice Generation and Validation. Endothelial cell-
specific Nox4 KO mice were generated by crossing Nox4 floxed
homozygous female mice with Tie2-Cre+ (endothelial cell-specific
promotor) (16) male mice. Neuronal and SMC-specific Nox4
KO mice were generated using inducible CaMKII− Cre+ (17)
and SMMHC− Cre+ (18) mice, respectively. While neuronal (nKO)
and SMC NOX4 KO (sKO) are tamoxifen-inducible mice lines,
endothelial NOX4 KO (eKO) mice bear a constitutive deletion.
Therefore, both SMC (sWT) and neuronal WT (nWT) require ta-
moxifen injections before studying their KO phenotype, and conse-
quently both share the tamoxifen-treated WT line as a control (n/
sWT) (SI Appendix, Fig. S3). Costaining of NOX4 and
CD31 showed the cell-specific absence of the NOX4 protein in
endothelial cells in the brain of endothelial Nox4 KO (eKO) mice
(Fig. 2B, Left, second row) but not in SMC-specific Nox4 KO (sKO)
(Fig. 2B, Left, fourth row). Using a similar costaining approach of
NOX4 and NeuN, no NOX4 could be detected in neurons of the
neuronal Nox4 KO (nKO) mice (Fig. 2B, Left, third row). As no
SMC could be stained in the brain, for control purposes, carotid
tissue was used to confirm that SMC of the sKO indeed do not
express NOX4 (Fig. 2B, Right). Collectively, this confirmed three
cell-specific Nox4 KO mouse lines: eKO (constitutive), nKO (in-
ducible), and sKO (inducible) (SI Appendix, Fig. S3). The
Tie2 promoter is also active in bone marrow. However, Nox4 ex-
pression was beyond the detection limit in both WT and Tie2-Cre+
mice while β-actin (internal control) and Nox2 signals, the major
immune cell NOX isoform, were strong and similar both in WT and
Tie2-Cre+ mice. These data suggest that macrophages/bone marrow
cells would not contribute to an eKO phenotype (SI Appendix,
Table S1).
Endothelial and Neuronal, but Not Smooth Muscle, NOX4 Deficiency
Improves Stroke Outcome. To examine the poststroke impact of
cell-specific eKO, sKO, and nKO of NOX4, 8- to 12-wk-old mice
were subjected to 1 h of tMCAO followed by 24 h of reperfusion.
TTC-stained brain sections showed a significant reduction of
infarct volume on day 1 after surgery in eKO and nKO compared
with WT mice, but not in sKO mice (Fig. 3A). As a clinical pa-
rameter, two independent neurological outcome parameters
were assessed, which measure global neurological and motor
A
B
C D
E
F
G
Fig. 1. Role of NOX4 in brain ischemia (blue), hindlimb ischemia (green),
and MI (red). (A) Infarct volume in Nox4 KO mice (blue) was reduced com-
pared with the WT mice (*P < 0.05, n = 8). (B) Quantified number of capil-
laries in the ischemic gastrocnemius muscle was not different between Nox4
KO (green, n = 16) and WT mice (white, n = 22). (C) Quantified number of
capillaries in the ischemic adductor muscle did not show a difference be-
tween Nox4 KO (green, n = 15) and WT mice (white, n = 19). (D) Blood flow
restoration decreased in the Nox4 KO mice (green, n = 17) at day 3, an effect
that was not seen in the long-term with Nox4 KO mice (green, n = 17) and
WT mice (black, n = 23) (*P < 0.05), showing the same blood flow at 28 d
after ischemia. (E) No significant differences in infarct size 4 wk after MI
between Nox4 KO (red, n = 25) and WT mice (white, n = 26). (F) Ejection
fraction decreased after MI with no significant change between Nox4 KO
(red, n = 23) and WT mice (black, n = 21). (G) Left ventricular function was
not different between Nox4 KO (red, n = 22) and WT mice (black, n = 20).
Representative staining pictures are shown above each graph.
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impairments, i.e., the Bederson score (Fig. 3B) and the Grip test
(Fig. 3C). Both outcome scores were significantly improved in
eKO and nKO but not in sKO mice, the latter showing even a
slightly deleterious outcome in the Grip test (Fig. 3C). These
data suggest a contribution of endothelial and neuronal but not
SMC NOX4 in stroke.
Differential Roles of Endothelial and Neuronal NOX4 in BBB Breakdown
and Neurotoxicity. Increased vascular permeability and subsequent
neurotoxicity are considered key contributors to poststroke path-
ophysiology (19). Since the localizations of NOX4 in mice (Fig.
2B) and humans (19) match these two pathomechanisms, we
hypothesized that NOX4 may contribute to both of them.
First, we assessed the role of NOX4 in BBB disruption by
functional quantification of poststroke edema formation using
extravasation of the vascular tracer, Evans blue, into the brain
parenchyma. Evans Blue extravasation was significantly reduced in
brains from eKO but not nKO mice, indicating a specific role of
eNox4 in poststroke BBB stability (Fig. 4A). Second, we quantified
neuronal cell death by costaining for the neuronal marker NeuN
and a TUNEL detection kit. Apoptotic neurons were reduced in
nKO (Fig. 4B) but not eKO mice (Fig. 4B). Necrotic cells were
also assessed in both eKO and nKO mice, showing similar results,
no effect in eKO, and reduction in nKO (SI Appendix, Fig. S4).
Autophagy may be an alternative pathomechanism in brain is-
chemia (20). Indeed, in stroked eKO versus WT mice the auto-
phagy marker, beclin-1, was significantly reduced (SI Appendix,
Fig. S5). Thus, BBB protection and smaller infarct in eNOX4 KO
are most likely linked to less autophagic stress and subsequently a
reduction in cell demise (21), while nNox4 KOmice showed direct
neuroprotection via an antiapoptotic mechanism.
To test the link of both observations to the enzymatic activity
of NOX4, i.e., ROS formation, we measured oxidative stress
using dihydroethidium staining of cryosections. ROS generation
was significantly reduced in the infarcted brains of both nKO and
eKO mice compared with their corresponding controls (Fig. 4C).
Thus, ROS formation appears to be a common denominator of
both eNOX4 and nNOX4.
Neuroprotective Effect of Neuronal NOX4 Inhibition Is Confirmed
by in Vivo and in Vitro Approaches in a Second Species. The stroke
therapy academic industry roundtable (STAIR) criteria recom-
mend that any result should be corroborated in another animal
species (www.thestair.org/) (22). Until now only mice have been
used to show that NOX4 inhibition reduces infarct volume and
neurological deficits following cerebral ischemia (9). To further
validate the role of NOX4 in stroke pathophysiology and outcome,
we extended our studies to rats using both in vitro and in vivo
models (Fig. 5A). We generated global Nox4 KO rats (SI Appendix,
Fig. S6) and confirmed the absence of Nox4 DNA markers by
genotyping (SI Appendix, Fig. S7) and brain, kidney, and lung
mRNA markers by qPCR including β-actin as internal control (SI
Appendix, Table S2). No phenotypic differences were observed in
the Nox4 KO rat compared with its respective WT. Nox4 KO rats
were then subjected to 90 min of tMCAO followed by 24 h of
reperfusion. Consistent with our in vivo observations in the mouse
model, Nox4 KO rats showed significantly smaller infarct volumes
compared with the WT littermates (Fig. 5B). Importantly, repli-
cating the protective effect of Nox4 deletion in a second species
further strengthens the attractive hypothesis of NOX4 inhibition as
a neuroprotective therapeutic approach for stroke patients.
We next used an in vitro rat hippocampal brain slice model
mimicking ischemic conditions by oxygen and glucose deprivation
(OGD), which allowed us (i) to corroborate our findings from the
in vivo studies, using a translationally more relevant pharmaco-
logical approach and (ii) to further analyze nNOX4 function in-
dependently of any functional vascular component. Hippocampal
brain slices were subjected for 15 min to OGD followed by 2 h of
reoxygenation in the presence or absence of the NOX inhibitors
GKT136901 (0.1 μM) or VAS2870 (10 μM). At the end of the
experiment, hippocampal cell death was assessed by the MTT assay,
and we observed that both NOX4 inhibitors were neuroprotective
after an OGD period (Fig. 5C). Similarly, oxidative stress measured
by the H2DCFDA probe was significantly reduced after 2 h of
reoxygenation under NOX inhibitor treatment (Fig. 5D). To sup-
port these findings, hippocampal brain slices from Nox4 KO mice
were subjected to OGD for 15 min followed by a 2-h reoxygenation
period. As expected, cell death (SI Appendix, Fig. S8A) and ROS
formation (SI Appendix, Fig. S8B) were significantly reduced in
Nox4 KO mice compared with their respective WT littermates.
Once both rodent species (mouse and rat) showed direct
neuroprotection and reduction of brain damage poststroke, we
extended our findings to a human in vitro model of BBB. Pri-
mary cultures of human brain microvascular endothelial cells
(HBMEC) were subjected to 6 h of hypoxia followed by 24 h of
reoxygenation in the presence or absence of a NOX4 inhibition
treatment. GKT136901 (1 μM) treatment significantly increased
cell viability after a hypoxic period in comparison with non-
treated cells (SI Appendix, Fig. S9), showing the possible po-
tential of translating this therapy to humans. In agreement with
our in vivo findings, similar in vitro ischemic conditions signifi-
cantly increased cell permeability after 24 h of reoxygenation
while treatment with GKT136901 (1 μM) prevented this detri-
mental effect as evidenced by a reduction in the diffusion of the
A
B
Fig. 2. Validation of cell-specific NOX4 deletion in mice in endothelial, neu-
ronal, and SMCs. (A, Left) Main cellular components of the neurovascular unit
are included in the scheme. NOX4 is predominantly expressed in some com-
ponents of the neurovascular unit such as endothelial cells (green), neurons
(green), and pericytes (green) rather than astrocytes (gray), macrophages
(gray), and microglia (gray). In fact, NOX4 play an important role in both BBB
leakage after stroke (red circle on left) and neuron-derived excitotoxicity (red
circle on right). Neuronal (NeuN) and endothelial (CD31) makers are also in-
cluded in red. (A, Right) Due to the lack of SMCs (green) in the brain, carotid
artery tissue was needed for the cell-specific Nox4 KO mice validation. SMC-
specific marker (αSMA) is in red. (B, Left, first row) Immunohistochemistry (IHC)
of brain tissue from a WT animal shows NOX4 expression (green) in neurons
(top and bottom arrowheads) and endothelial cells (middle arrow). (B, Left,
second row) IHC shows no expression of endothelial NOX4 in eNox4 KO
(see merged panels) while NOX4 is still expressed in neurons (arrows). (B,
Left, third row) Neuronal NOX4 is not expressed (green, all arrows) where
neurons are detected by the specific tissue marker NeuN (red). (B, Left,
fourth row) sNOX4 KO presents NOX4 expression (green) in both neuronal
(arrow) and endothelial cells (arrowhead). Since specific expression of
NOX4 in SMCs is not possible to detect in brain tissue, carotid tissue is used.
(B, Right, first row) Carotid artery sections from WT mice show SMCs (red)
and NOX4 (green) expression. (B, Right, second row) Carotid tissue from
sNOX4 KO animals show no expression of NOX4 (green) in SMCs in com-
parison with WT sections. DNA was visualized using Hoechst dye.
Casas et al. PNAS | November 14, 2017 | vol. 114 | no. 46 | 12317
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dextran tracer (3 and 70 kDa) (SI Appendix, Fig. S10 A and B)
and Evans Blue extravasation (SI Appendix, Fig. S10C) through a
monolayer of HBMEC.
Using a combined preclinical meta-analysis, we previously estab-
lished that NOX1 plays no role in brain ischemia (12). Nevertheless,
GKT136901 has been described as a NOX1/NOX4 inhibitor (23)
and may have acted also via NOX1. To test this possibility, Nox4 KO
mice were subjected to 1 h tMCAO and treated 1 h poststroke
with GKT136901 (10 mg/kg), showing no additional effect over
nontreated Nox4 KO animals (SI Appendix, Fig. S11). Therefore,
these data suggest that NOX1 plays no role in the action of
GKT136901 and that NOX4-driven neurotoxicity can be phar-
macologically prevented using isoform-specific NOX inhibitors
that inhibit massive ROS production and oxidative damage.
Hence, pharmacological modulation of NOX4 could lead to di-
rect neuroprotection and improvement of BBB stability.
Discussion
Here we elucidate one mechanism: why, of all organs, the brain
has the highest sensitivity to hypoxia/ischemia. The induction of
NOX4, a primary source of ROS, in many tissues during hypoxia
(9–11) suggested that NOX4 may be a uniform target for post-
ischemic cytoprotective therapies. Surprisingly, however, we
found the role of NOX4 in ischemia to be highly specific to the
brain, i.e., in ischemic brain stroke, and not to be involved in lung
ischemia (24), myocardial IR, or hindlimb ischemia. We have
previously shown that the predominant localizations of NOX4 in
the mouse and human brain, pre- and poststroke, are in endo-
thelial cells and neurons (9). At the mRNA level, other cells
have been described to express NOX4, which, however, does not
translate to detectable levels at the protein level. By examining
cell-specific Nox4 KO mice, we provide clear evidence on how
endothelial and neuronal Nox4 have a major impact in brain
A
B C
Fig. 3. Endothelial and neuronal, but not SMC-specific NOX4 KO reduces brain infarct and neurological scores. (A) eKO (dark blue) and nKO (light blue) show
smaller infarct sizes compared with WT mice (white) (***P < 0.001, n = 23), sKO mice (cyan) did not show decreased infarcts (n = 12). Complete sets of brain
slices from a representative animal (TTC staining) are shown above the graph. (B) Neurological outcome was improved in eKO and nKO in comparison with
WT mice (**P < 0.01, n = 23). However, no protection on neurological function was observed in sKO (n = 12). (C) Motor function was also enhanced in eKO
and nKO in comparison with WT mice (***P < 0.001, n = 23), but not in sKO mice (*P < 0.05). The n/sWT mice were treated with tamoxifen based on their
respective n/sKO mice. The eWT mice were not treated since eKO have a constitutive deletion.
A B C
Fig. 4. Contribution of endothelial and neuronal NOX4 to BBB breakdown, neuronal apoptosis, and ROS formation. (A) BBB integrity as assessed by Evans blue
extravasation was preserved in the eKO (dark blue) but not in the nKO (light blue) at day 1 after 1 h of tMCAO (*P < 0.05, n = 6). Complete set of brain slices from
a representative animal are shown above the graph. (B) nKO presented fewer apoptotic cells in comparison with nWT (*P < 0.05, n = 5) while no effect was shown
in eKOmice (n = 5). Representative staining panels are shown above the bar graph. (C) Both eKO and nKOmice showed decreased oxidative stress compared with
their respective WT littermates (***P < 0.001, n = 5). Representative staining pictures are shown above the graph.
12318 | www.pnas.org/cgi/doi/10.1073/pnas.1705034114 Casas et al.
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vulnerability to ischemia. However, we cannot exclude that
Nox4 minor expression in other cells may also contribute, in
smaller percentages, to the observed phenotype. For example,
pericytes have been suggested to play an important role in the
formation and maintenance of the BBB, leading to a detrimental
role in acute ischemia (25). Moreover, Nox4 has been recently
considered as the major source of ROS in human pericytes
(26). However, the fact that the endothelial and neuronal Nox4
KO mice add up completely to the global NOX4 KO phenotype
would suggest that in our stroke model pericyte contribution is
indeed rather minor and endothelial and neuronal cells con-
stitute the main sources of NOX4 relevant to stroke damage.
One key explanation for the brain-specific role of NOX4 ap-
pears to reside in the BBB, which differentiates the brain from
the heart and other organs (24). We identify endothelial NOX4,
but not vascular smooth muscle nor neuronal NOX4, as the key
source of ROS triggering to breakdown upon an ischemic stroke.
In heart and vascular periphery such leakage and edema may
also occur but is apparently less detrimental (25). Indeed, we
find that NOX4 inhibition prevents BBB leakage in a human
BBB in vitro model. It will be worth exploring whether in other
organs with a blood–tissue barrier, e.g., the placenta (26) or
mammary glands, a similar pathological relevance during ische-
mia or hypoxia is observed.
A second unexpected mechanism is that NOX4 can cause direct
neuronal autotoxicity. Previously, NOX4 was thought to be pri-
marily relevant in the vasculature. Neuronal autotoxicity in stroke,
also termed excitotoxicity, was previously ascribed primarily to
nitric oxide overproduction (27) and neurotrauma (28). However,
both in vivo and also importantly in an ex vivo brain slice model free
of BBB effects, neuronal NOX4 was clearly a major contributor to
cellular autotoxicity upon ischemia or hypoxia. Pharmacological
inhibition of NOX4 was also neuroprotective, providing proof-of-
concept for the drugability of this component of NOX4’s actions
as well.
Both cellular mechanisms explain why NOX4 inhibition is such a
powerful experimental therapeutic approach in stroke (9). It di-
rectly prevents two damage-trigger mechanisms: the breakdown of
the BBB and the subsequent neuronal autotoxicity.
To better estimate whether these mouse data may be translat-
able into the clinic as a first-in-class cytoprotective therapy in
stroke, future experiments should confirm NOX4’s role in a second
species and then translate it to humans. It is therefore reassuring
that the essential role of NOX4 in stroke is preserved in a second
rodent species using a Nox4 KO rat and by pharmacological in-
tervention in a human brain microvascular endothelial cell model.
Subsequent studies in large-animal stroke models and preparation
for a clinical trial are ongoing (European Research Council–Proof
of Concept Project 737586 SAVEBRAIN).
This study cannot elucidate why the substantial induction of
NOX4 and subsequent ROS formation in heart and hindlimb
and other organs (29) does not lead to tissue damage. However,
this is reminiscent of the induction of NOX4 in the lung during
hypoxia (9) and ischemia (26), respectively, which is also not
detrimental. Previous studies looking at the short-term effects
(after 24 h) showed either no (30) or a detrimental role (31) of
NOX4 in heart ischemia. We are aware that Nox4 has been
proposed to be one of the major sources of ROS in failing hearts
(26), playing a key role in cardiac failure (32) and mitochondrial
growth (33) and dysfunction in heart tissue (34). However, our
findings do not indicate a short-term effect in heart ischemia.
Likewise, looking at long-term outcomes in hindlimb and MI
models, where the assessment was performed 4 wk after surgery,
we detected no significant effect. With respect to the hindlimb
model of ischemia, a variation of this model using an artery ex-
cision technique, which results in more inflammation and sur-
rounding tissue damage, NOX4 is protective (11, 35, 36), which
may involve NOX4’s anti-inflammatory role (36, 37). Using a
pure ischemic hindlimb model, different KO strategy, and an-
esthesia, we find no role for NOX4.
In conclusion, we elucidate the superior sensitivity of the brain
compared with other organs to ischemic damage at the cellular
level by NOX4-dependent neuronal autotoxicity and BBB break-
down. Our findings also provide a clear rational for further de-
velopment of NOX4 inhibitors as a first-in-class neuroprotective
strategy in stroke.
Materials and Methods
Detailed methods are provided in SI Appendix, SI Materials and Methods.
Animals. All animal experiments were approved by local state authorities
(Regierung von Unterfranken) as well as by the German Animal Welfare Act,
the Dutch law on animal experiments, and the Ethics Committee of the
Faculty of Medicine, Universidad Autónoma de Madrid (Madrid).
Cell-Specific Nox4 KO Mice Generation. Constitutive Nox4 KO mice and floxed
Nox4 mice were generated as described (9). To generate endothelial-specific
Nox4 KO (eNox4 KO) mice, female mice were bred with male mice that express
the Cre recombinase gene under control of the endothelial-cell–specific Tie2
promotor (18). During breeding, only males that bear the Cre gene were selected
for future breeding rounds, while females were not allowed to bear the Cre. For
experiments Cre+ (eNox4 KO) males were used. SMC-specific and neuron-specific
Nox4 KO mice were generated in an analogous way using SMMHC-CreERT2 mice
(18) and CamKII Cre (17) mice, respectively.
Stroke Surgery (tMCAO Model). The model was previously established as
described for mice (9) and rat (38) surgery.
Brain Infarct Volume Measurements. The ischemic lesion was measured 24 h
after MCAO using TTC staining (38).
Murine Model of Hindlimb Ischemia. The right femoral artery was perma-
nently ligated. A suture (5-0 silk) was placed around the femoral artery in
#
** *
###
* *
A
B C
D
Fig. 5. Validation of NOX4 in a second animal species by using tMCAO in
NOX4 KO rats and NOX4 inhibitors in hippocampal brain slices subjected to
OGD. (A) Similarly to the mouse model, occlusion of the middle cerebral
artery was performed in WT and Nox4 KO rats. Rat hippocampal brain slices
were subjected to oxygen and glucose deprivation. After treatment, cell
viability and ROS formation (CA3) were measured. (B) Infarct volume in Nox4
KO rats was decreased compared with theWT littermate [*P < 0.05, n = 11 (WT)
and n = 9 (KO)]. Complete sets of brain slices from a representative animal (TTC
staining) are shown above the graph. (C) Cell death (#P < 0.05) was signifi-
cantly reduced in hippocampal brain slices treated with 0.1 μMGKT136901 and
10 μM VAS2870 as NOX inhibitors (*P < 0.05, **P < 0.01, n = 6). (D) ROS
formation (###P < 0.001) was also decreased after NOX inhibition (*P < 0.05,
n = 5).
Casas et al. PNAS | November 14, 2017 | vol. 114 | no. 46 | 12319
PH
A
RM
A
CO
LO
G
Y
D
ow
nl
oa
de
d 
at
 U
N
IV
E
R
S
IT
E
IT
 M
A
A
S
T
R
IC
H
T
 o
n 
O
ct
ob
er
 3
0,
 2
02
0 
between the branching of the arteria epigastrica and the a. poplitea. These
last two arteries were also ligated to prevent collateral flow and backflow,
respectively. The wound was then closed with a 4-0 polysorb suture.
MI and IR of the Heart Models. Using a left thoracotomy, the left descending
coronary artery was ligated with a 6-0 polyprolene suture permanently for
MI. For the transient ischemia of 45 min, a small polyethylene tube was
inserted under the ligature, compressing the coronary artery, which was then
removed after the ischemic period.
Hippocampal Brain Slices. In vitro damage caused by oxygen–glucose depri-
vation/reoxygenation and the protection elicited by NOX inhibitors was
studied in rat hippocampal slices. Brains from 2- to 3-mo-old male Sprague-
Dawley rats (250–300 g) or Nox4 KO mice (2–3 mo) were isolated and sub-
jected to OGD as previously described (39).
HBMEC Culture Subjected to Hypoxia. HBMECs (Cell Systems) were cultured
to ∼90% confluence. Cell medium was replaced for non-FBS–containing
medium (2 mL/well) following 6 h of hypoxia (94.8% N2, 0.2% O2, and 5%
CO2). The hypoxia period was followed by 24 h of reperfusion in the pres-
ence or absence of 1 μM GKT136901 (Genkyotech) as treatment.
Statistics. All mice and in vitro data are expressed as mean ± SEM. Rat in vivo
experiments are expressed as mean ± SD. Using the GraphPad Prism 5.0
software package statistical differences were determined by Student’s two-
tailed t test and Mann–Whitney test experiments. For repeated measure-
ments, a two-way ANOVA was used. Statistical comparisons between groups
were performed using one-way ANOVA. The number of animals necessary
to detect a standardized effect size on infarct volumes ≥0.2 was determined
via a priori sample-size calculation. P values < 0.05 were considered statisti-
cally significant.
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